EquityBulls

Keywords Selected: AurobindoPharma

Research

Aurobindo Pharma - Entry into India - a little too late?

Stock Report

ANVISA Approval for CuraTeQ Biologics' Biosimilars Manufacturing Facility
Aurobindo Pharma USA Inc completes acquisition of Lannett Company, Inc
Completion of US FDA Inspection at Auroactive Pharma Pvt Ltd
Aurobindo Pharma USA Receives FTC Approval to Acquire Lannett Company
Completion of US FDA Pre-Approval Inspection at Eugia Steriles Private Limited
Classification of US FDA Inspection at Unit-III of Eugia Pharma Specialities Ltd, Pashamylaram as OAI
Aurobindo Pharma receives final US FDA approval for Tofacitinib Tablets, 5 mg and 10 mg
Aurobindo Pharma Inaugurates TheraNym - Pioneering India's Large-Scale Biologics Contract Manufacturing Facility
Classification of Unit-I of Eugia Pharma Specialities Ltd, Shameerpet as OAI
CuraTeQ Biologics Secures Health Canada NOC for Bevqolva™ Bevacizumab Biosimilar
Aurobindo Pharma receives USFDA Approval for Dextromethorphan Polistirex ExtendedRelease Oral Suspension, 30 mg/5 mL (OTC)
Aurobindo Pharma receives USFDA Approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL
Aurobindo Pharma receives USFDA Approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
Aurobindo Pharma receives USFDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
CuraTeQ Biologics announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11
CuraTeQ Biologics Pvt Ltd enters into agreement with STADA Arzneimittel AG
Classification of Unit-V of Apitoria Pharma Ltd as VAI by the US FDA
Eugia Pharma Specialities Ltd receives OAI classification from USFDA for Unit 2
Unit-IV of APL Healthcare Ltd classified as VAI by the US FDA
Eugia Pharma announces launch of Pomalidomide Capsules in the US
Completion of US FDA Inspection at Unit I of Eugia Pharma Specialities Ltd., Shameerpet
Eugia Pharma receives USFDA Approval for Everolimus Tablets
CuraTeQ Biologics Pvt Ltd and BioFactura Inc, USA to terminate agreement mutually
APL Healthcare Ltd's Unit-4 gets 5 observations from USFDA